ZNL-05-044 is a CDK11 inhibitor with an IC50s of 0.23 μM and 0.27 μM against CDK11A and CDK11B, respectively (NanoBRET assay). ZNL-05-044 leads to G2/M cell cycle arrest and impairs RNA splicing[1].

ZNL-05-044 is a CDK11 inhibitor with an IC50s of 0.23 μM and 0.27 μM against CDK11A and CDK11B, respectively (NanoBRET assay). ZNL-05-044 leads to G2/M cell cycle arrest and impairs RNA splicing[1].

ZNL0325 is a covalent probe based on pyrazolopyrimidine. ZNL0325 features an acrylamide side chain at the C3 position, which is capable of forming covalent bonds with multiple kinases that possess a cysteine at the αD-1 position, including BTK, EGFR, BLK, and JAK3. ZNL0325 can be used in the research of creating structurally distinct covalent kinase […]

ZO-1/TJP1 Antibody is an unconjugated, approximately 191 kDa, rabbit-derived, anti-ZO-1/TJP1 polyclonal antibody. ZO-1/TJP1 Antibody can be used for: WB, ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, pig, and predicted: mouse, rat, chicken, dog, cow, rabbit, guinea pig background without labeling.

Zolantidine dimaleate (SKF 95282 dimaleate) is a potent, selective and cross the blood-brain barrier histamine H2 antagonist. Zolantidine dimaleate induces antinociception[1][2].

Zolertine hydrochloride is an α-adrenoceptor antagonist with a pKi of 6.81 in rat liver (α1B-adrenoceptors) and 6.35 in rabbit liver (α1A-adrenoceptors) membranes[1].

Zolimidine, a derivate of imidazopyridine, is an orally active antiulcer agent. Zolimidine stimulates mucus secretion in intestinal mucosal cells and enhacnes intestinal wall more resistant to ulceration. Zolimidine exhibits gastroprotective effect in duodenal ulcer research[1][2].

Zolimidine, a derivate of imidazopyridine, is an orally active antiulcer agent. Zolimidine stimulates mucus secretion in intestinal mucosal cells and enhacnes intestinal wall more resistant to ulceration. Zolimidine exhibits gastroprotective effect in duodenal ulcer research[1][2].

Zolimidine, a derivate of imidazopyridine, is an orally active antiulcer agent. Zolimidine stimulates mucus secretion in intestinal mucosal cells and enhacnes intestinal wall more resistant to ulceration. Zolimidine exhibits gastroprotective effect in duodenal ulcer research[1][2].

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].

Zongertinib (BI 1810631) is a potent and selective HER2 and EGFR tyrosine kinase inhibitor with IC50 values of 13 nM and 579 nM, respectively. Zongertinib has antitumor activity and can be used in the study of multiple solid tumors[1][2][3].

Zoniporide dihydrochloride (CP-597396 dihydrochloride) is a potent and selective inhibitor of highly water-soluble sodium hydrogen exchange type 1 (NHE-1). Zoniporide dihydrochloride inhibits NHE1 dependent 22Na+ uptake in vitro with an IC50 of 14 nM. Zoniporide has antitumor activity[1][2].

Zorevunersen sodium is an antisense oligonucleotide that is intended to increase the level of productive SCN1A mRNA and consequently increase the expression of the sodium channel Nav1.1 protein. Zorevunersen sodium is used for the study of Dravet syndrome.

Zorifertinib (AZD3759) hydrochloride is a potent, orally active, central nervous system-penetrant, EGFR inhibitor (IC50s: 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively). Zorifertinib hydrochloride induces cancer cell apoptosis. Zorifertinib hydrochloride has antitumor activity, and can be used for NSCLC, HCC etc. research[1][2].

Zosurabalpin TFA is a tethered macrocyclic peptide antibiotic, acting specifically on A. baumannii. Zosurabalpin TFA inhibits lipopolysaccharide-transport[1].

Zotiraciclib (TG02) is an orally active potent inhibitor of CDK2, JAK2 and FLT3 with IC50 values of 13, 73, and 56 nM, respectively. Zotiraciclib can be used for the research of advanced leukemias and multiple myeloma[1][2].

Zovostotug is a human CD163 (scavenger receptor cysteine-rich (SRCR) type 1 M130) mAb[1].

Zoxamide (RH-7281) is an oomycete fungicide. Zoxamide arrests nuclear division in Phytophthora capsici germlings and destroyed the microtubule cytoskeleton[1][2].

Zuclomiphene-d5 (citrate) is the deuterium labeled Zuclomiphene citrate[1]. Zuclomiphene citrate is a cis isomer of Clomiphene citrate. Zuclomiphene citrate has an antiestrogenic effect and can inhibit the secretion of luteinizing hormone (LH) more than the trans isomer. Zuclomiphene citrate is also an orally active hypocholesterolemic agent[2][3][4][5].

Zuclopenthixol decanoate is a long-acting agent for schizophrenia and other serious mental illnesses research[1].

Zuclopenthixol ((Z)-Clopenthixol) dihydrochloride is a thioxanthene derivative which acts as a mixed dopamine D1/D2 receptor antagonist. Zuclopenthixol dihydrochloride is used in the study of schizophrenia[1][2][3].

Zurletrectinib is a potent tyrosine kinase inhibitor. Zurletrectinib serves as an antineoplastic agent. Zurletrectinib can used for research of preventing TRK-mediated related diseases, such as tumors[1][2].

ZW290 is a compound to activate brown adipose tissue (BAT) thermogenic function. ZW290 increases the expression of uncoupling Protein 1 (UCP1) protein and inhibits ATP synthesis in BAT[1].

ZX-J-19j (Compound ZX-J-19j) is a cyclophilin J inhibitor. ZX-J-19j showes potent antitumor activity[1].

ZY-1 is a control molecule of ZY-2 (HY-D1876, a PKM2 fluorescent probe). ZY-1 shows a low fluorescence emission in HeLa, a cervical cancer cell abundant in PKM2 expression[1].

ZY-1 is a control molecule of ZY-2 (HY-D1876, a PKM2 fluorescent probe). ZY-1 shows a low fluorescence emission in HeLa, a cervical cancer cell abundant in PKM2 expression[1].

ZY-1 is a control molecule of ZY-2 (HY-D1876, a PKM2 fluorescent probe). ZY-1 shows a low fluorescence emission in HeLa, a cervical cancer cell abundant in PKM2 expression[1].

ZY-1 is a control molecule of ZY-2 (HY-D1876, a PKM2 fluorescent probe). ZY-1 shows a low fluorescence emission in HeLa, a cervical cancer cell abundant in PKM2 expression[1].

ZY-2 is a specific fluorescent probe for pyruvate kinase M2 (PKM2). ZY-2 can image in PKM2-positive cells in a time- and concentration-dependent manner. ZY-2 can be used for the detection of cancer cells[1].

Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury[1].

Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury[1].

Zymostenol (5a-Cholest-8-en-3b-ol) is a late-stage precursor in the biosynthesis of cholesterol. Zymostenol is a RORγ agonist (EC50: 1 μM)[1][2][3].

Zymosterol is a Cholesterol (HY-N0322) biosynthesis metabolite. Zymosterol, a precursor of Cholesterol, is found mostly in the plasma membrane. Zymosterol circulates within the cell[1][2].

ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC50s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase[1].

α1-2 Fucosidase (EC 3.2.1.51) is a highly specific exoglycosidase that catalyzes the hydrolysis of linear α1-2 linked fucose residues from oligosaccharides[1].

alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) (EC 2.4.1.65) (Hp3/4FT) can be found in Helicobacter pylori. alpha-1,3/4-Fucosyltransferase (α1,3/4FucT) catalyzes fucose transfer from donor GDP-beta-l-fucose to the GlcNAc[1].

α-1,4-N-Acetylglucosaminyltransferase 4 (EC 2.4.1, A4GNT) catalyzes the transfer of N-acetylglucosamine (GlcNAc) to core 2 branched O-glycans and suppresses H. pylori growth[1].

α-1,4-N-Acetylglucosaminyltransferase 4 (EC 2.4.1, A4GNT) catalyzes the transfer of N-acetylglucosamine (GlcNAc) to core 2 branched O-glycans and suppresses H. pylori growth[1].

α-1,4-N-Acetylglucosaminyltransferase 4 (EC 2.4.1, A4GNT) catalyzes the transfer of N-acetylglucosamine (GlcNAc) to core 2 branched O-glycans and suppresses H. pylori growth[1].

alpha-1,6-Fucosidase (LpAlfC(E274A)) (EC 3.2.1.51) cleaves branched non-reducing terminal fucose, linked α(1-6) to the core N-acetylglucosamine of N-linked oligosaccharides. alpha-1,6-Fucosidase (LpAlfC(E274A)) is useful for determining core fucosylation[1].

alpha-2,3-Sialyltransferase (PmST3) (EC 2.4.99.4) is a beta-galactoside. alpha-2,3-Sialyltransferase (PmST3) catalyzes the transfer of sialic acid to carbohydrate groups of glycoproteins and glycolipids[1].

alpha-2,6-Sialyltransferase (Pd26ST) (EC 2.4.99.1) is capable of sialylating both terminal and internal galactose and N-acetylgalactosamine, which producing terminal α2,6-sialosides[1].

α-Acetobromoglucose is a biochemical reagent that can be used as a biological material or organic compound for life science related research.

α-Acetolactate decarboxylase, from Bacillus subtilis is an enzyme responsible for acetoin production, and can be widely used in food processing[1].

α-Amylase-IN-4 (Compd 10y) show maximum inhibition of amylase activity with IC50 value 17.83 ± 0.14 μg/mL[1].

α-Amylase-IN-5 (compound 3a) is a α-amylase inhibitor, with an IC50 of 18.8 mM[1].

α-Amylase/α-Glucosidase-IN-3 (Compound 17) is an α-Amylase/α-Glucosidase dual inhibitor, with IC50s of 0.70 μM and 1.10 μM. α-Amylase/α-Glucosidase-IN-3 can be used for research of type-II diabetes mellitus[1].